VRDN vs. FLGT, CSTL, VCYT, CDNA, SERA, PMD, GH, ARWR, RDNT, and FTRE
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Veracyte (VCYT), CareDx (CDNA), Sera Prognostics (SERA), Psychemedics (PMD), Guardant Health (GH), Arrowhead Pharmaceuticals (ARWR), RadNet (RDNT), and Fortrea (FTRE). These companies are all part of the "medical" sector.
Viridian Therapeutics (NASDAQ:VRDN) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.
Fulgent Genetics received 198 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 73.02% of users gave Viridian Therapeutics an outperform vote while only 60.70% of users gave Fulgent Genetics an outperform vote.
Fulgent Genetics has higher revenue and earnings than Viridian Therapeutics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viridian Therapeutics currently has a consensus target price of $36.60, suggesting a potential upside of 141.42%. Fulgent Genetics has a consensus target price of $30.00, suggesting a potential upside of 49.18%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Fulgent Genetics.
In the previous week, Viridian Therapeutics and Viridian Therapeutics both had 2 articles in the media. Viridian Therapeutics' average media sentiment score of 1.23 beat Fulgent Genetics' score of -0.34 indicating that Viridian Therapeutics is being referred to more favorably in the media.
48.1% of Fulgent Genetics shares are held by institutional investors. 1.4% of Viridian Therapeutics shares are held by insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Viridian Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.
Fulgent Genetics has a net margin of -58.03% compared to Viridian Therapeutics' net margin of -75,711.48%. Fulgent Genetics' return on equity of -3.04% beat Viridian Therapeutics' return on equity.
Summary
Fulgent Genetics beats Viridian Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
